Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.68 |
| ▸ | SLC5A1 | P13866 | 16/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12257257 | 0.91 | SLC5A2 (0.64) | SLC5A2SLC5A1HRH1CYP3A4 | |
| SCHEMBL12309055 | 0.84 | SLC5A2 (0.58) | SLC5A2SLC5A1HRH1 | |
| SCHEMBL12257550 | 0.81 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL12257494 | 0.81 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL12257556 | 0.81 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL12257227 | 0.79 | SLC5A2 (0.76) | SLC5A2SLC5A1 | |
| SCHEMBL12336710 | 0.79 | SLC5A2 (0.43) | SLC5A2SLC5A1HRH1CYP3A4 | |
| SCHEMBL16313573 | 0.79 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL12257573 | 0.77 | SLC5A2 (0.69) | SLC5A2SLC5A1 | |
| SCHEMBL12257569 | 0.76 | SLC5A2 (0.65) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017792-B2 | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017792-B2 | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-7910619-B2 | e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910619-B2 | e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | SLC5A1, SLC5A2, SLC5A11 | SLC5A2 2/4885SLC5A1 1/4885HRH1 4240/4885 |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | SLC5A1, SLC5A2, SLC5A11 | SLC5A2 2/4885SLC5A1 1/4885HRH1 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.